Radiopharm Theranostics Limited · ASX:RAD
Radiopharm Theranostics — Joint Meeting of EORTC, NCI and AACR 2022
8 slides from Radiopharm Theranostics's conference presentation, Oct 28, 2022
Slide 1: Pivalate Achieves Positive Phase II Data in Brain Mets Trial
PIVALATE ACHIEVES POSITIVE PHASE II DATA IN BRAIN METS TRIAL Presentation at a Joint Meeting of the European Organisation for Research and Treatment of Cancer (EORTC), the (USA) National Cancer Institute (NCI), and the America Association for Cancer Research (AACR) in Barcelona, Spain, 26-28 Oct 202
Slide 2: Background
PIVALATE DELIVERS POSITIVE PHASE II DATA IN BRAIN METS TRIAL Background • F18-Pivalate is a novel radiotracer for the detection, characterisation and progression monitoring of glioblastoma and brain metastases • F18-Pivalate targets fatty acid synthetase, selectively overexpress by tumors, but not b
Slide 3: RAD 101 Phase II trial overview
PIVALATE DELIVERS POSITIVE PHASE II DATA IN BRAIN METS TRIAL RAD 101 Phase II trial overview • The RAD 101 Phase IIa open label trial performed F18-Pivalate PET/MRI in patients with one or more cerebral metastases from different primary tumours of origin; breast, lung, melanoma and colorectal cancer
Slide 4: RAD 101 Phase IIa Trial Results
PIVALATE DELIVERS POSITIVE PHASE II DATA IN BRAIN METS TRIAL RAD 101 Phase IIa Trial Results • Under the Phase IIa trial, F-18 Pivalate PET showed high uptake regardless of origin of primary tumor. This indicates that Pivalate can be used to detect & monitor cerebral metastases • Patients without pr
Slide 5: Pivalate Platform Next Steps
PIVALATE DELIVERS POSITIVE PHASE II DATA IN BRAIN METS TRIAL Pivalate Platform Next Steps: • RAD 101 (Diagnostic) • RAD 102 (Therapeutic) • Scientific Advisory Board to conclude detailed analysis of the • Select final therapeutic candidate Phase IIa data and ascertain the most appropriate use case i
Slide 6: Brain Mets Market Opportunity
BRAIN METS MARKET OPPORTUNITY Prostate cancer is a large radiopharmaceutical imaging indication that received FDA approval. We therefore see this as the best proxy in assessing Radiopharm’s potential market opportunity for its brain mets indication Eligible New Companies with New US Cases Price Per
Slide 7: 18F-Fluoropivalate PET/MRI: imaging of treatment naïve and radiosurgery-treated patients
PIVALATE DELIVERS POSITIVE PHASE II DATA IN BRAIN METS TRIAL RAD CODE MOLECULE INDICATION DX / TX ISOTOPE COUNTRY PRECLINICAL PHASE I PHASE II PHASE III NOTES RAD 101 pivalate Brain Mets Dx F18 UK Positive Phase II achieved 18F-Fluoropivalate PET/MRI: imaging of treatment naïve patients and patients
Slide 8: Six Platforms, 9 Well Differentiated Molecules
SIX PLATFORMS, 9 WELL DIFFERENTIATED MOLECULES ONE OF THE DEEPEST PIPELINES IN RADIOPHARMACEUTICAL THERAPIES 4 Nano-mAbs Avb6 Integrin Pivalate PSA-mAb DUNP19 PTPm 81 patients dosed 88 patients dosed 61 patients dosed • 4 Single chain • Peptide • Small molecule • mAb • mAb • Peptide mAbs molecule mo
Radiopharm Theranostics — Joint Meeting of EORTC, NCI and AACR 2022 on 6ix